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Abstract
Background: The sensitivity of endoscopic ultrasound (EUS) in staging gastro-oesophageal cancers (GOCs) has
been widely studied. However, the economic evidence of EUS staging in the management of patients with GOCs is
scarce. This review aimed to examine all economic evidence (not limited to randomised controlled trials) of the use
of EUS staging in the management of GOCs patients, and to offer a review of economic evidence on the costs,
benefits (in terms of GOCs patients’ health-related quality of life), and economic implications of the use of EUS in
staging GOCs patients.
Methods: The protocol was registered prospectively with PROSPERO (CRD42016043700; http://www.crd.york.ac.uk/
PROSPERO/display_record.php?ID=CRD42016043700). MEDLINE (ovid), EMBASE (ovid), The Cochrane Collaboration
Register and Library (including the British National Health Service Economic Evaluation Database), CINAHL
(EBSCOhost) and Web of Science (Core Collection) as well as reference lists were systematically searched for studies
conducted between 1996 and 2018 (search update 28/04/2018). Two authors independently screened the
identified articles, assessed study quality, and extracted data. Study characteristics of the included articles, including
incremental cost-effectiveness ratios, when available, were summarised narratively.
Results: Of the 197 articles retrieved, six studies met the inclusion criteria: three economic studies and three economic
modelling studies. Of the three economic studies, one was a cost-effectiveness analysis and two were cost analyses. Of
the three economic modelling studies, one was a cost-effectiveness analysis and two were cost-minimisation analyses.
Both of the cost-effectiveness analyses reported that use of EUS as an additional staging technique provided, on
average, more QALYs (0.0019–0.1969 more QALYs) and saved costs (by £1969–£3364 per patient, 2017 price year)
compared to staging strategy without EUS. Of the six studies, only one included GOCs participants and the other five
included oesophageal cancer participants.
Conclusions: The data available suggest use of EUS as a complementary staging technique to other staging
techniques for GOCs appears to be cost saving and offers greater QALYs. Nevertheless, future studies are necessary
because the economic evidence around this EUS staging intervention for GOCs is far from robust. More health
economic research and good quality data are needed to judge the economic benefits of EUS staging for GOCs.
PROSPERO Registration Number: CRD42016043700.
Keywords: Costs, Effects, QALYs, Economic review, Endoscopic ultrasound, EUS staging, Staging techniques,
Gastro-oesophageal cancers
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Background
Gastro-oesophageal (oesophageal or gastric, or both) cancers
(GOCs) are one of the most common cancers in the UK
with approximately 16,000 people diagnosed in 2015 [1, 2].
Oesophageal and gastric cancers were the seventh and four-
teenth most common cause of cancer death respectively in
the UK in 2016, as shown from the latest available statistics
reported by the Cancer Research United Kingdom (CRUK)
[1, 2]. It is estimated that a total of around 12,500 people
died from these cancers in 2016 – that is 34 deaths per day
[1, 2]. Accurate staging of GOCs is vital for determining
prognosis and planning appropriate treatment. Accurate sta-
ging in the management of GOCs will not only help avoid
unnecessary surgical interventions but also will ultimately
help reduce the financial pressure on the NHS, which is par-
ticularly important given the limited resources available to
cancer services and the growing incidence of GOCs [3].
Accurate staging of GOCs can be achieved by a
combination of investigative techniques. The tech-
niques used for staging GOC include computer tom-
ography (CT), endoscopic ultrasound (EUS), positron
emission tomography (PET) and adjuncts to staging
include magnetic resonance imaging (MRI), bronchos-
copy, laparoscopy and trans-abdominal ultrasound [4].
CT has been recommended for use at initial staging
assessment to determine whether the cancer cells
have spread from the primary site of its origin into
new areas of the body (i.e. metastasis); but in the ab-
sence of metastatic disease, EUS has been advocated
as the preferred technique for the assessment and
prediction of operability [4]. This is due to the fact
that EUS is superior to CT for local regional staging
of oesophageal and gastric tumours [4].
Studies and guidelines for the management of oesophageal
and gastric cancer have reported that EUS has superior
tumour invasion (T) and loco-regional nodal (N) staging
ability over CT and PET given its sensitivity, particularly for
detection of regional lymph node metastases, although the
complementary nature of these investigative techniques
must be recognised [5–10]. The sensitivity of EUS for sta-
ging of GOC has been widely evaluated; however, the eco-
nomic evidence of EUS staging in the management of GOC
patients is scarce. Furthermore, the effectiveness and cost-ef-
fectiveness of EUS staging of GOC had not been assessed,
particularly in the form of randomised controlled trials
(RCT), until the establishment of “COGNATE” trial - a
HTA-funded RCT UK study [11].
Given that the economic evidence of EUS for staging of
GOC is scant, conducting a systematic review of the eco-
nomic evidence on EUS staging in patients with GOC is
therefore important. It not only gives a meaningful evidence-
based insight, from an economic perspective, for researchers
and clinical experts in this field but also healthcare commis-
sioners. In view of that, this systematic review aimed to
examine all economic evidence (not just from RCTs) of the
use of EUS staging in the management of patients with
GOC. Systematic reviews of economic evaluations review
studies that evaluated both the effectiveness in terms of
health effects (usually measured as life-years gained (LYGs)
or quality-adjusted-life-years (QALYs), accounting for the
quality-of-life outcomes) and cost of the alternative interven-
tions assessed. Economic evaluation is performed by under-
taking either a cost-effectiveness analysis (CEA), cost-utility
analysis (CUA), cost-consequences analysis (CCA), cost-
benefit analysis (CBA) or cost-minimisation analysis (CMA).
When clinical outcome expressed in natural units (e.g. LYGs,
lives saved, improvement in pain score etc) are used as health
effects in an economic analysis, this is often referred to as
CEA with its parameter of interest being called incremental
cost-effectiveness ratio (ICER). Whereas, when QALY, a
common unit, is used as health effect in an economic ana-
lysis, then this is often referred to as CUA though CEA is
preferred by some authors and the resulting parameter of
interest is called incremental cost-utility ratio (ICUR). The
ICER/ICUR is then compared with the official or approxi-
mate willingness to pay (WTP) ceiling ratio for a unit of ef-
fect, that is, threshold used for decision making. CCA reports
costs and outcomes in disaggregated form for each alterna-
tive [12]. CBA converts clinical outcomes into monetary
units so that a net benefit (or cost) can be estimated [12].
CMA measures which alternative has the least cost, this
method is only applied when the outcomes of alternative in-
terventions have been proven to be equivalent. The protocol
of this systematic review was registered prospectively with
PROSPERO, an international prospective register of system-
atic reviews (Registration number 2016:CRD42016043700;
http://www.crd.york.ac.uk/PROSPERO/display_record.
php?ID=CRD42016043700) [13]. This paper offers a review
of economic evidence on the costs, benefits (in terms of
GOC patients’ health-related quality of life), and economic
implications of the use of EUS for staging GOC patients.
Methods
This review was carried out and reported in accordance
with the published updated Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines [14, 15].
Searches and study selection
Searches for this systematic review were conducted using a
range of electronic databases: MEDLINE (ovid), EMBASE
(ovid), The Cochrane Collaboration Register and Library (in-
cluding Cochrane Central Register of Controlled Trials
(CCRCT), Cochrane Reviews, Database of Abstracts of
Reviews of Effects (DARE), Health Technology Assessment
(HTA), British National Health Service Economic Evaluation
Database (NHS EED), Cochrane Methodology Register
(CMR)), CINAHL (EBSCOhost), Web of Science (Core
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Collection). Searches were restricted to publications from the
last 20 years (1996–2016) as per the registered protocol on
PROSPERO (Registration number 2016:CRD42016043700)
[13]. To ensure that the review was as up-to-date as possible,
the searches were re-run on all databases to cover 2016–
2018 (search update on 28/04/2018).
In order to ensure a comprehensive search was
achieved and any relevant research had not been missed,
online searches were also conducted through the follow-
ing internet search engines and appropriate websites to
identify grey literature, reports, ongoing and unpublished
studies from conference papers and abstracts: Google,
Google Scholar, Department of Health (DoH), National
Institute for Health and Clinical Excellence (NICE),
National Institute for Health Research (NIHR) Journals
Library, NIHR UK Clinical Trials Gateway, The National
Cancer Research Institute (NCRI), Cancer Research
Wales (CRW), Wales Cancer Research Centre (WCRC),
Welsh Government (WG), Health and Care Research
Wales (HCRW), CRUK and other relevant charitable or-
ganisation websites.
The reference lists of papers that were included in the
review were searched for further publications that had
not been identified in the electronic searches. Contacts
with study authors were made to locate further relevant
literature and publications.
Guided by the review objectives, the search terms as
shown in Table 1 were developed using the PICO frame-
work [16, 17]. The PICO framework was utilised to help
shape, design and construct the search process to iden-
tify all relevant published and unpublished materials
from various sources. Titles, abstracts and full-text pa-
pers were searched for using these search terms.
The search strategy for each of the five electronic da-
tabases was developed, checked and tested by an infor-
mation specialist before finalising the search terms; this
process was informed by the search strategy of a wider
evidence synthesis that includes a systematic review of
non-economic studies of treatments for resectable
adenocarcinoma of the stomach, gastro-oesophageal
junction and lower oesophagus [18]. An example of
search strategy used in the Medline Ovid database is as
shown in the additional file (see Additional file 1).
Inclusion and exclusion criteria
Table 2 presents the inclusion and exclusion criteria,
using the economic evidence review design framework
outlined in the University of York Centre for Reviews
and Dissemination (2009) [12]: Population, Interven-
tions, Comparators, Outcomes, and Type of Evidence.
Due to resources constraints, only studies written in
English were included. This includes international stud-
ies that have been translated or written in English.
Data extraction
Titles and abstracts of all studies identified were screened
and assessed for relevance against the inclusion criteria by
two independent reviewers (STY and NB). The inclusion
or exclusion of each study was checked and confirmed.
All potentially relevant full-text papers were then obtained
and screened against the inclusion criteria, with disagree-
ments resolved through discussion until agreements were
achieved collectively. Disagreements occurred when for
example the reviewers had different views on whether a
retrieved paper should be included in the review.
Following screening, relevant information from all full-
text papers included in the review were extracted by the
primary reviewer (STY) using an adapted standardised
form [12], and checked by the second reviewer (NB).
Two adapted standardised forms were developed and
used for data extraction – one for economic studies and
another for economic modelling studies.
Quality assessment
The quality of all full-text papers included in the review
were assessed and rated independently by the two re-
viewers using the Critical Appraisal Skills Programme
(CASP) economic evaluation checklist [19] tool for eco-
nomic studies and the Philips et al’s economic modelling
checklist [20] tool for economic modelling studies. The
papers were critically appraised to assess to what extent
the content of these papers complied with the criteria of
good practice in economic evaluation and if there was
any obvious bias. Disagreements between the reviewers
were resolved through discussion until agreements were
achieved collectively. Disagreements occurred when for
example the reviewers had different score on an in-
cluded paper.
Data synthesis
All studies included in the review were summarised and
compared across studies in a narrative form to answer the
review objectives. The aims, methods, and results of the
studies reviewed were synthesised narratively. This demon-
strates the heterogeneity of the studies in terms of charac-
teristics [12]. Due to the heterogeneity of the studies in
terms of the study type and outcomes across the studies,
meta-analysis was not appropriate [12]. Costs were con-
verted into British pounds sterling, £, using the appropriate
exchange rate published in the International Monetary
Fund [21] and inflated to 2017 price year using the hospital
and community health services (HCHS) index [22–25] for
the studies included in the review.
Results
Literature search: identification of studies
Overall, the search from 1996 to 2016 identified 197
potentially relevant studies, six of which fulfilled the
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Table 1 Search terms by category, guided by PICO framework, for the systematic review
No. Search Term Category Search Terms
1. Disease neoplas* OR
cancer*OR
carcin* OR
tumo* OR
adenocarcinoma* OR
squamous cell carcinoma* OR
malig* OR
metasta*
AND
2. Type of disease gastro* OR
oesophag* OR
esophag* OR
gastro-oesophag* OR
gastro-esophag* OR
gastroesophag* junction* OR
gastro-esophag* junction* OR
gastrooesophag* junction* OR
gastro-oesophag* junction* OR
esophagogastric junction* OR
esophago-gastric junction* OR
oesophagogastric junction* OR
oesophago-gastric junction* OR
oesophageal squamous cell carcinoma* OR
esophageal squamous cell carcinoma* OR
gut* OR
gullet* OR
food pipe OR
stomach OR
upper GI OR
upper-GI OR
upper gastrointestin* OR
upper-gastrointestin* OR
upper digestive tract* OR
upper-digestive tract* OR
intraepithelial OR
intramucosal OR
node* OR
nodal
AND
3. Intervention endosono* OR
EUS OR
endoscopic ultraso* OR
endoscopic-ultraso* OR
EUS-FNA OR
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Table 1 Search terms by category, guided by PICO framework, for the systematic review (Continued)
No. Search Term Category Search Terms
EUS-fine needle aspiration OR
EUS fine-needle aspiration OR
Endosonography-guided FNA OR
Endoscopic ultrasound-fine needle
aspiration OR
Endoscopic ultrasound-guided fine needle
aspiration OR
Endoscopic ultrasound-guided fine-needle
aspiration OR
Endoscopic-ultrasound-guided fine-needle
aspiration OR
Endoscopic ultrasound guided fine needle
aspiration OR
Echoendoscop* OR
Echo-endoscop*
AND
Staging OR
Preoperative staging OR
Pre-operative staging
AND
4. Outcome econom* OR
health economics OR
economic evaluation OR
cost-effective* OR
cost effect* OR
cost utility OR
cost-utility OR
cost-conseq* OR
cost conseq* OR
cost-benefit OR
cost benefit OR
cost-minimisation OR
cost minimisation OR
cost-minimization OR
cost minimization OR
cost* OR
cost* analys* OR
unit cost OR
unit-cost OR
unit-costs OR
unit costs OR
drug cost OR
drug costs OR
hospital costs OR
health-care costs OR
health care cost OR
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inclusion criteria and were included in the review
(Fig. 1). Of the six studies included, three were eco-
nomic analysis studies and three were economic model-
ling studies.
To ensure that the review was as up-to-date as pos-
sible, the searches were re-run on all databases to cover
2016–2018 (search update on 28/04/2018); 30 poten-
tially relevant papers were identified but none met the
inclusion criteria. In such case, the final number of stud-
ies included in the review remained at six.
Study descriptions
Tables 3 and 4 summarises the characteristics of the six
studies included in the review. There were three economic
analysis studies (Table 3) and three economic modelling
studies (Table 4). Five of the studies included in the review
were US studies, and one was a UK study. Of the three eco-
nomic analysis studies, two were cost analyses [26, 27] and
one was a cost-effectiveness analysis [11]. Of the three
economic modelling studies, two were cost-minimisation
analyses [29, 30] and one was a cost-effectiveness analysis
[31]. All of the three economic modelling studies used deci-
sion tree modelling techniques to explore staging strategies.
The six studies included in the review differed quite
markedly in terms of their design. Only one study used
primary cost and outcome data collected in prospective
evaluation [11], one study used data collected in pro-
spective case series [27], one study used retrospective
data [26], and the remaining three studies synthesised
data from secondary sources in a decision tree model
[29–31]. Of the six studies, only one [11] was a rando-
mised controlled trial and included participants diag-
nosed with gastro-oesophageal cancer (i.e. oesophageal,
gastro-oesophageal junction or gastric cancer); the
other five were non-trial studies and included partici-
pants diagnosed with oesophageal cancer. Amongst the
six studies, Russell et al. (2013) [11] was again the only
study which evaluated costs of health care resource use
Table 1 Search terms by category, guided by PICO framework, for the systematic review (Continued)
No. Search Term Category Search Terms
medical cost OR
medical costs OR
cost* efficacy* OR
cost* analys* OR
cost* allocation* OR
cost* control* OR
cost* illness* OR
cost* affordable* OR
cost* fee* OR
cost* charge*
economic model* OR
markov* OR
budget* OR
healthcare economics OR
health care economics OR
cost analys* OR
health-care cost* OR
health care cost* OR
hrqol OR
Health related quality of life OR
health-related quality of life OR
quality-adjusted life year* OR
quality adjusted life year* OR
qaly OR
Quality of life OR
quality-of-life OR
QoL
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covering secondary care contacts and hospital pre-
scribed drugs in addition to cost of EUS, collected pro-
spectively in the trial.
In terms of health outcome measures, two studies
[11, 31] included quality-adjusted life year (QALY)
as the measure of effect and conducted a cost-effect-
iveness analysis to assess the gain in QALYs relative
to the costs of different staging strategies. The
remaining four studies [26, 27, 29, 30] did not ex-
plore QALY or other quality of life measures but
only cost.
Quality assessment
Each of the six studies included in the review were critic-
ally appraised against the appropriate source of quality ap-
praisal checklist: the CASP economic evaluation checklist
[19] was used for the three economic studies, and Philips
et al’s economic modelling checklist [20] was used for the
remaining three economic modelling studies. Table 5 and
Table 6 summarised the quality assessment of the three
economic studies and three economic modelling studies,
respectively.
Table 5 shows the study quality of the three economic
studies was generally good, scoring on average greater
than 75%, although only one study [11] met all quality cri-
teria on the CASP economic evaluation checklist. The
study by Shumaker et al. (2002) [26] scored the second
highest, followed by Chang et al. (2003) [27]. Of these
three economic studies, two had missing key information:
Chang et al. (2003) [27] reported neither cost perspective,
cost inflation, discounting nor price year, and sensitivity
analysis was not undertaken; likewise, Shumaker et al.
(2002) [26] did not state whether their reported costs were
discounted or inflated as appropriate.
Table 6 shows the study quality of the three eco-
nomic modelling studies included in the review was
Table 2 Inclusion and exclusion criteria for the systematic review
Inclusion Criteria Exclusion Criteria
Population All adults (aged 19 and above) who had cancer
(i.e. localised tumour) of the oesophagus,
stomach or gastro-oesophageal junction; free
of metastatic disease.
Population aged below 19 years and had metastatic
oesophageal, gastro-oesophageal or gastric cancer.
Interventions Use of endoscopic ultrasound (EUS) (also known
as endosonography, echoendoscopy) staging
in patient with oesophagus, gastro-oesophageal
and gastric cancer.
Use of endoscopy only or ultrasound only, and use
of EUS for non-cancer staging purposes e.g. treatment
of cancer
Comparators Standard staging algorithm e.g. trans-abdominal
ultrasound scan, computed tomography (CT) scan.
Partial economic evaluations, when no formal
comparator was used, were included.
Outcomes All relevant full economic evaluation studies
outcomes including (but not be restricted to)
cost per QALY and cost per life-year gained;
All other relevant economic outcomes including
(but not be restricted to) resource use, direct and
indirect costs, incremental benefits e.g. quality-adjusted
survival or quality-adjusted life years (QALYs),
health-related quality of life, cancer-specific quality of life
and utility gained – this includes partial economic
evaluation studies outcomes, which costs or consequences
alone of a single intervention (e.g. EUS staging of GOC)
were described, were included.
All outcomes unrelated to economic evidence of EUS
staging of the oesophagus, gastro-oesophageal junction
or gastric cancer.
Type of
Evidence
Full economic evaluation evidence (i.e. cost-effectiveness,
cost-utility and cost-benefit analyses) related to EUS staging
of oesophageal, gastro-oesophageal junction and gastric
cancer were considered.
Other economic studies that contain partial economic
evaluation or no evaluation context (e.g. cost analyses,
cost-description studies, cost-outcome descriptions,
budgetary studies, outcome-description studies in terms
of utility gained, health-related quality of life and
cancer-specific quality of life measures such as QALYs
and FACT-G score) were also considered.
Economic evaluation studies conducted alongside RCTs,
non-RCTs, quasi-experimental trials, epidemiological research,
cohort studies, and modelling studies were considered.
Non-research studies such as editorials, case reports or other
descriptive studies.
General Language – English.
Years – 1996-2016 and 2016–2018
Language – Not written or translated into English.
Years – Before 1996.
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satisfactory, scoring moderately well on the Philips et
al’s economic modelling checklist. In descending order
of quality, the study by Wallace et al. (2002) [31]
scored the highest followed by Harewood et al. (2002)
[30] and Hadzijahic et al. (2000) [29]. One study [29]
did not state the perspective of the model and all three
[29–31] did not specify the time horizon of the deci-
sion tree model. There was insufficient detail of how
parameters in the model were identified [31] and how
data were modelled [30]. There was also a lack of clar-
ity with regards to the source of probabilities and cost
data used in the decision tree model [29].
Data synthesis results
All of the six studies included in the review exhibit EUS
as a complementary imaging technique to other imaging
modalities such as CT and PET scanning for staging gas-
tro-oesophageal cancer. This is in agreement with a pre-
viously published meta-analysis study of diagnostic test
characteristics for EUS, CT, and PET scanning [8], conclud-
ing that the three approaches were complementary.
Results from three of the economic studies [11, 26, 27]
show staging of oesophageal or gastro-oesophageal cancer
with EUS could potentially save costs. Similarly, results from
two of the modelling studies [29, 30] show that EUS or
EUS-fine-needle aspiration biopsy (FNA) is the least costly
staging technique for oesophageal cancer. The study by
Wallace et al. (2002) [31] shows that EUS-FNA in addition
to CT scan is the least costly strategy than all other strat-
egies i.e. CT alone, CT+ thoracoscopy and laparoscopy (TL),
CT+ EUS-FNA+TL, CT + PET+EUS-FNA and PET+EUS-
FNA.
Results from the two studies [11, 31] in which quality-
adjusted life year (QALY) and cost data were available
demonstrate the use of EUS [11] or EUS-FNA [31] as an
additional staging technique for gastro-oesophageal can-
cer offered more QALYs and costed less, on average,
compared to staging techniques without EUS. Russell et
Fig. 1 Flowchart of the study selection process
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al. (2013) [11] reported that EUS resulted in a QALY
gain of 0.1969 QALYs and saved costs by £2860, on
average, per patient (£3364 per patient, 2017 price year);
combining these benefits and savings demonstrates that
EUS is likely to be cost-effective with a probability of
96% at the UK NICE’s threshold of £20,000–£30,000 per
QALY [28].
Similarly, Wallace et al. (2002)‘s [31] modelling study
showed that using EUS-FNA as an additional staging tech-
nique offered greater QALYs and saved more costs, on aver-
age, than staging strategy without EUS. For example, the
combination of CT and EUS-FNA (CT+EUS-FNA) pro-
vided 0.0019 more QALYs and saved US$1790, on average,
per patient (£1969 per patient, 2017 price year) compared to
CT alone strategy. The authors argued that, among all the
six staging strategies evaluated (i.e. CT alone, CT+ EUS-
FNA, CT+TL, CT +EUS-FNA+TL, CT+ PET+EUS-FNA
and PET+EUS-FNA), CT+ EUS-FNA was the least costly
strategy (US$40,363) (£44,392, 2017 price year) and offered
higher QALYs on average (0.9649) than all other strategies
with the exception of PET+EUS-FNA (US$44,521 for
1.0336 QALYs) (£48,965, 2017 price year). The latter was
slightly more effective (by 0.0687 QALYs on average) but
more costly (by US$4158 on average [£4573, 2017 price
year]) compared with CT+ EUS-FNA, yielding a marginal
cost-effectiveness ratio of US$60,544 per QALY (£66,588
per QALY, 2017 price year), a ratio that is less than that of
other medical treatments but above accepted thresholds in
the USA and UK.
Discussion
Main findings
This systematic review of economic evidence of EUS staging
in patients with GOC revealed a considerably small number
of relevant studies. Studies varied in quality, study design
and method. Study quality was generally satisfactory across
Table 5 Quality assessment results of economic studies included in the systematic review
Question
no.
CASP economic evaluation checklist questionsab Response
(√, x, NC or NA)
Studies (author and year)
Shumaker et al.
(2002) [26]
Chang et al.
(2003) [27]
Russell et al.
(2013) [11]
1 Was a well-defined question posed? √ √ √
2 Was a comprehensive description of the competing
alternatives given?
NA NA √
3 Does the paper provide evidence that the programme
would be effective (i.e. would the programme do more
good than harm)?
√ √ √
4 Were the effects of the intervention identified, measured
and valued appropriately?
NA NA √
5a Were all important and relevant resources required and
health outcome costs for each alternative identified?
NC NC √
5b Were all important and relevant resources required and
health outcome costs for each alternative measured in
appropriate units?
√ √ √
5c Were all important and relevant resources required and
health outcome costs for each alternative valued credibly?
√ NC √
6 Were costs and consequences adjusted for different
times at which they occurred (discounting)?
x x √
7 What were the results of the evaluation? √ √ √
8 Was an incremental analysis of the consequences and
cost of alternatives performed?
NA NA √
9 Was an adequate sensitivity analysis performed? √ x √
10 Is the programme likely to be equally effective in your
context or setting?
√ √ √
11 Are the costs translatable to your setting? x x √
12 Is it worth doing in your setting? √ √ √
Score, ratio™ (%) 8/11 (73%) 6/11 (55%) 14/14 (100%)
NA Not Applicable, NC Not Clear
a[19] Available from: http://www.casp-uk.net/casp-tools-checklists
bAdapted from: Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University
Press, 1987
™Ratio = b/a, where b = sum of tick; a = sum of items (excluding ‘NA’ items)
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Table 6 Quality assessment results of economic modelling studies included in the systematic review
Quality
Criterion
Philips et al’ economic modelling checklist questionsa Response
(√, x, NC or NA)
Studies (author and year)
Hadzijahic et al.
(2000) [29]
Harewood et al.
(2002) [30]
Wallace et al.
(2002) [31]
S1 Is there a clear statement of the decision problem? √ √ √
Is the objective of the evaluation and model specified
and consistent with the stated decision problem?
√ √ √
Is the primary decision-maker specified? NC √ √
S2 Is the perspective of the model stated clearly? x √ √
Are the model inputs consistent with the
stated perspective?
NC √ √
Has the scope of the model been stated
and justified?
√ √ √
Are the outcomes of the model consistent with the
perspective, scope and overall objective of the model?
√ √ √
S3 Is the structure of the model consistent with a coherent
theory of the health condition under evaluation?
√ √ √
Are the sources of data used to develop the structure
of the model specified?
√ √ √
Are the causal relationships described by the model
structure justified appropriately?
NA NA NA
S4 Are the structural assumptions transparent and justified? √ √ √
Are the structural assumptions reasonable given the overall
objective, perspective and scope of the model?
√ √ √
S5 Is there a clear definition of the options under evaluation? √ √ √
Have all feasible and practical options been evaluated? √ √ √
Is there justification for the exclusion of feasible options? NA NA NA
S6 Is the chosen model type appropriate given the decision
problem and specified causal relationships within the model?
√ √ √
S7 Is the time horizon of the model sufficient to reflect all
important differences between options?
x x X
Are the time horizon of the model, the duration of treatment
and the duration of treatment effect described and justified?
x x X
S8 Do the disease states (state transition model) or the
pathways (decision tree model) reflect the underlying
biological process of the disease in question and the
impact of interventions?
√ √ √
S9 Is the cycle length defined and justified in terms of the
natural history of disease?
NA NA NA
D1 Are the data identification methods transparent and
appropriate given the objectives of the model?
√ NC √
Where choices have been made between data sources,
are these justified appropriately?
NA √ √
Has particular attention been paid to identifying data
for the important parameters in the model?
√ √ X
Has the quality of the data been assessed appropriately? x x x
Where expert opinion has been used, are the methods
described and justified?
NA NA x
D2 Is the data modelling methodology based on justifiable
statistical and epidemiological techniques?
√ NC √
D2a Is the choice of baseline data described and justified? √ √ √
Are transition probabilities calculated appropriately? NA NA NA
Has a half-cycle correction been applied to both
cost and outcome?
NA NA NA
If not, has this omission been justified? NA NA NA
D2b If relative treatment effects have been derived
from trial data, have they been synthesised using
NA NA NA
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Table 6 Quality assessment results of economic modelling studies included in the systematic review (Continued)
Quality
Criterion
Philips et al’ economic modelling checklist questionsa Response
(√, x, NC or NA)
Studies (author and year)
Hadzijahic et al.
(2000) [29]
Harewood et al.
(2002) [30]
Wallace et al.
(2002) [31]
appropriate techniques?
Have the methods and assumptions used to extrapolate
short-term results to final outcomes been documented
and justified?
NA NA NA
Have alternative assumptions been explored through
sensitivity analysis?
√ √ √
Have assumptions regarding the continuing effect of
treatment once treatment is complete been documented
and justified?
NA NA NA
Have alternative assumptions regarding the continuing
effect of treatment been explored through sensitivity analysis?
NA NA NA
D2c Are the costs incorporated into the model justified? √ √ √
Has the source for all costs been described? √ √ √
Have discount rates been described and justified
given the target decision-maker?
NC NA √
D2d Are the utilities incorporated into the model appropriate? NA NA √
Is the source for the utility weights referenced? NA NA X
Are the methods of derivation for the utility weights justified? NA NA X
D3 Have all data incorporated into the model been described
and referenced in sufficient detail?
NC √ √
Has the use of mutually inconsistent data been justified
(i.e. are assumptions and choices appropriate)?
NC NC √
Is the process of data incorporation transparent? √ x X
If data have been incorporated as distributions,
has the choice of distribution for each parameter
been described and justified?
NA NA NA
If data have been incorporated as distributions,
is it clear that second order uncertainty is reflected?
NA NA NA
D4 Have the four principal types of uncertainty been addressed? X x X
If not, has the omission of particular forms of
uncertainty been justified?
X x X
D4a Have methodological uncertainties been addressed by
running alternative versions of the model with different
methodological assumptions?
X x X
D4b Is there evidence that structural uncertainties have been
addressed via sensitivity analysis?
X x X
D4c Has heterogeneity been dealt with by running the
model separately for different subgroups?
x x x
D4d Are the methods of assessment of parameter
uncertainty appropriate?
√ √ √
If data are incorporated as point estimates, are the ranges
used for sensitivity analysis stated clearly and justified?
NC √ √
C1 Is there evidence that the mathematical logic of the
model has been tested thoroughly before use?
x x x
C2 Are any counterintuitive results from the model explained and justified? NA NA NA
If the model has been calibrated against independent data, have any differences been
explained and justified?
NA NA NA
Have the results of the model been compared with those of previous models and any
differences in results explained?
x x x
Score, ratio™ (%) 21/38 (55%) 24/38 (63%) 28/43 (65%)
NA Not Applicable, NC Not Clear
aAvailable from [20]: Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, Woolacott N and Glanville J. Review of guidelines for good practice in
decision-analytic modelling in health technology assessment. Health Technol Assess 2004;8(36)
™Ratio = b/a, where b = sum of tick; a = sum of items (excluding ‘NA’ items)
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all the studies included in the review, but only one of these
studies [11] met all reporting and quality criteria. Differences
in study design make it difficult to draw definitive conclu-
sions as to whether the use of EUS as an additional staging
technique could be considered cost-effective i.e. value for
money which can be assessed by comparing the costs (mon-
etary term) and health effects (non-monetary term) of an
intervention with the alternative. Health effect of an inter-
vention is usually measured in terms of QALYs (Quality-
Adjusted Life Years), a summary measure of health outcome
and also a common unit used for economic evaluation of an
intervention, as recommended by the UK’s NICE (The Na-
tional Institute for Health and Care Excellence) [28]. Given
the differences in study design, a head-to-head comparison
of the results couldn’t be made from the Russell et al. (2013)
[11] and Wallace et al. (2002) [31] studies to draw definitive
conclusions. Although both of these studies had evaluated
both costs and QALYs, their respective study designs were
too different to allow direct comparison; one was an eco-
nomic evaluation study using primary data [11] and the
other an economic modelling study using secondary data
[31]. Nevertheless, the economic evidence identified in this
review, especially the better quality studies, provided useful
findings on the value of EUS staging in the management of
GOC patients, which could be of importance to policy-
makers and healthcare commissioners.
Among the six studies included in the review, two
studies [11, 31] are the most robust in terms of includ-
ing and comparing the relative costs and QALYs of dif-
ferent staging strategies, for example GOC staging with
and without EUS. Findings from both of these two
studies demonstrated that use of EUS as an additional
imaging technique could save costs and offer greater
QALY gains. This could be due to the fact that EUS
has been known to be beneficial in terms of its sensitiv-
ity for locoregional staging of GOC [4, 6, 8, 32–34]. For
that reason, using EUS as a complementary imaging
technique to other imaging techniques such as CT and
PET scanning for staging GOC could undoubtedly help
minimise unnecessary treatments [4, 35, 36]; and thus
potentially could save costs and offer greater health
benefits to patients in terms of QALY gains. The EUS
cost saving evidence was also supported by the
remaining four studies [26, 27, 29, 30] evaluating only
the cost of EUS e.g. whether EUS is a cost saving strat-
egy or the least costly staging strategy. Russell et al.
(2013) [11] further argued that EUS has a considerably
high probability of being cost-effective under current
recommended UK NICE’s threshold of £20,000 to £30,
000 per QALY [28]. Thus, despite the scarcity of eco-
nomic evidence in this field, from these studies identi-
fied in the review, there is some positive economic
evidence relating to the cost-effectiveness of EUS in the
management of patients with GOC.
Strength and limitations of review methods
This review adds to the literature by providing critical
evaluation of the health economics evidence of EUS sta-
ging in gastro-oesophageal cancers (GOCs), for which
there is a lack of well-conducted economic studies.
Though a systematic review in this field was published
20 years ago [37], this systematic review is the most up-
to-date collection of economic literature in this area.
Twenty years on since the review by Harris et al. (1998)
[37], still only six papers were found in the area of health
economics of EUS staging in GOC. This shows that
there is a lack of prioritisation of research in this area.
Broad search terms were used to develop a compre-
hensive search strategy for each of the databases used in
this systematic review. The resultant retrieved studies
were quality appraised, using both the published stand-
ard checklists recommended for use in assessing the
quality of economics articles in systematic review – the
Critical Appraisal Skills Programme (CASP) economic
evaluation checklist [19] and the Philips et al’s economic
modelling checklist [20] for the retrieved economic stud-
ies and economic modelling studies, respectively. The
narrative summary of the review not only described the
economic evidence of EUS staging in GOC but also
served as a platform for providing a holistic insight into
the health economics research available to date in this
area. The latter is particularly helpful for commissioners,
clinicians and researchers to elicit information and po-
tentially to facilitate the development of further research
in this area.
This review has several limitations. Heterogeneity of
the included studies in the review in terms of study de-
signs and methods meant that a meta-analysis of studies
was not possible and a narrative summary was used. We
also acknowledge that different countries have different
thresholds for both the investigation of, and surgical
management of gastro-oesophageal malignancies. This
can result in variation between practices and hence diffi-
culty in translating financial recommendations across re-
gions. In terms of impact that EUS has on patients’
quality of life and its costs, the lack of the availability of
health economics research in this area means that it is
considerably difficult, particularly for commissioners and
clinicians, to guide evidence-based practice from an eco-
nomic perspective.
Further research
This systematic review shows that the economic evi-
dence available to date in this area is still scarce.
There was a lack of health economic research collect-
ing data, especially primary data, on both costs and ef-
fects (such as utility values to construct QALYs) of
EUS staging in GOC. To improve this, there is a need
for more primary health economic research in this
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area, particularly integrated clinical and economic tri-
als of EUS staging in GOC that can offer robust evi-
dence of costs and effects.
Conclusions
Despite the lack of economic evidence on costs and ben-
efits of EUS staging for GOC, the data available from
this review suggest use of EUS as a complementary sta-
ging technique to other staging techniques for GOC ap-
pears to be cost saving and offers greater QALYs. Based
on the only randomised controlled trial conducted in
the UK identified in this review, EUS seems to have high
probability of being cost-effective at the UK NICE’s
threshold of £20,000–£30,000 per QALY. Nevertheless,
future studies are necessary because the economic evi-
dence around EUS staging interventions for GOC is far
from robust. More health economic research and good
quality data are needed to judge the economic benefits
of EUS staging for GOC, particularly primary health eco-
nomic research that collects primary data on the costs
and effects (such as QALYs) of EUS staging in GOC.
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